A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT05722015
Phase
PHASE3
Status
Active Not Recruiting

Conditions

  • Metastatic Non-small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pembrolizumab Formulated with Berahyaluronidase Alfa — BIOLOGICAL
    Pembrolizumab (+) Berahyaluronidase alfa SC will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
  • Pemetrexed — DRUG
    Pemetrexed 500 mg/m² by IV Infusion will be administered for nonsquamous NSCLC as per the schedule specified in arm.
  • Cisplatin — DRUG
    Cisplatin 75 mg/m² by IV Infusion will be administered for nonsquamous and squamous NSCLC as per the schedule specified in arm.
  • Carboplatin — DRUG
    Carboplatin AUC 5 mg/mL/min in nonsquamous and AUC 6 mg/mL/min in squamous NSCLC will be administered as per the schedule specified in arm.
  • Paclitaxel — DRUG
    Paclitaxel 200 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
  • Nab-paclitaxel — DRUG
    Nab-paclitaxel 100 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
  • Pembrolizumab — BIOLOGICAL
    Pembrolizumab by IV Infusion will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
  • Filgrastim — DRUG
    Filgrastim will be administered as per the schedule specified for the arm.
  • Pegylated filgrastim — DRUG
    Pegylated filgrastim will be administered as per the schedule specified for the arm.

Study Details

This study is to assess the pharmacokinetics (PK) and safety of SC pembrolizumab formulated with berahyaluronidase alfa (MK-3475A) versus (vs) intravenous (IV) pembrolizumab (MK-3475), administered with chemotherapy in first line treatment of adult participants with metastatic non-small cell lung cancer. The primary hypotheses of this study are pembrolizumab formulated with berahyaluronidase alfa subcutaneous (SC) is noninferior to pembrolizumab IV with respect to PK parameters.

Key Dates

Start date
Feb 14, 2023
Status verified
Sep 2025
Primary completion
Jul 12, 2024
Completion
May 22, 2028

Study Design

Enrollment
377 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy
    Participants with treatment-naïve metastatic NSCLC receive 790 mg of Pembrolizumab Formulated With Berahyaluronidase Alfa via subcutaneous (SC) injection on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy.
  • Active Comparator: Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy
    Participants with treatment-naïve metastatic NSCLC receive 400 mg pembrolizumab intravenous (IV) infusion in combination with platinum doublet chemotherapy.

Primary Outcome Measure

Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose [ Time Frame: Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days) ]

Locations (9)

FacilityCityStateZIPSite coordinators
St. Joseph's Hospital and Medical Center-Dignity Health Cancer Institute ( Site 0023)PhoenixArizona85004-
Clermont Oncology Center ( Site 0018)ClermontFlorida34711-
Mid Florida Hematology and Oncology Center ( Site 0010)Orange CityFlorida32763-
University of Illinois at Chicago-University of Illinois Cancer Center ( Site 0022)ChicagoIllinois60612-
Orchard Healthcare Research Inc. ( Site 0011)SkokieIllinois60077-
Franciscan Health Lafayette East ( Site 0020)LafayetteIndiana47905-
Mercy Health-Paducah Cancer Center ( Site 0006)PaducahKentucky42003-
Hattiesburg Clinic Hematology/Oncology ( Site 0008)HattiesburgMississippi39401-
Central Care Cancer Center - Bolivar ( Site 0017)BolivarMissouri65613-

Related coverage on Hipa.ai

Find similar trials in Phoenix, AZ

By research site
St. Joseph's Hospital and Medical Center-Dignity Health Cancer Institute· Phoenix, AZClermont Oncology Center· Clermont, FLMid Florida Hematology and Oncology Center· Orange City, FLUniversity of Illinois at Chicago-University of Illinois Cancer Center· Chicago, ILOrchard Healthcare Research Inc.· Skokie, ILFranciscan Health Lafayette East· Lafayette, IN

Related Studies